Bristol-Myers Squibb (NYSE:BMY) Stock Holdings Trimmed by Rockland Trust Co.

Rockland Trust Co. lowered its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 10.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 175,253 shares of the biopharmaceutical company's stock after selling 20,035 shares during the quarter. Rockland Trust Co.'s holdings in Bristol-Myers Squibb were worth $10,689,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. LaFleur & Godfrey LLC raised its holdings in Bristol-Myers Squibb by 3.5% in the 4th quarter. LaFleur & Godfrey LLC now owns 43,551 shares of the biopharmaceutical company's stock valued at $2,463,000 after acquiring an additional 1,487 shares during the last quarter. Brighton Jones LLC increased its stake in Bristol-Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock valued at $1,116,000 after purchasing an additional 4,935 shares during the last quarter. Sovran Advisors LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at $274,000. Leavell Investment Management Inc. boosted its stake in Bristol-Myers Squibb by 7.1% in the 4th quarter. Leavell Investment Management Inc. now owns 39,008 shares of the biopharmaceutical company's stock worth $2,206,000 after buying an additional 2,582 shares during the last quarter. Finally, TFB Advisors LLC grew its holdings in Bristol-Myers Squibb by 14.9% in the 4th quarter. TFB Advisors LLC now owns 4,787 shares of the biopharmaceutical company's stock valued at $271,000 after buying an additional 621 shares during the period. Institutional investors and hedge funds own 76.41% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Piper Sandler started coverage on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price target on the stock. UBS Group reduced their target price on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a report on Friday, April 11th. The Goldman Sachs Group restated a "neutral" rating and set a $55.00 price target (down from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Argus raised Bristol-Myers Squibb to a "hold" rating in a research note on Friday, April 25th. Finally, Cantor Fitzgerald restated a "neutral" rating and issued a $55.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $58.00.

Insider Transactions at Bristol-Myers Squibb

In related news, EVP Samit Hirawat acquired 4,250 shares of the stock in a transaction that occurred on Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the purchase, the executive vice president now directly owns 83,513 shares in the company, valued at $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Stock Performance

BMY traded down $0.99 during trading hours on Friday, hitting $49.71. 9,394,854 shares of the stock were exchanged, compared to its average volume of 13,000,634. The stock has a market cap of $101.15 billion, a price-to-earnings ratio of -11.25, a price-to-earnings-growth ratio of 2.07 and a beta of 0.38. The stock has a 50-day simple moving average of $48.78 and a 200-day simple moving average of $54.83. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.50 by $0.30. The business had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company's quarterly revenue was down 5.6% on a year-over-year basis. During the same period in the previous year, the business posted ($4.40) EPS. Analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.